STAT News

STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming

The FDA said it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.

By STAT News

1 min read
STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights